Analytical Data
-
Gene name
Spink2
- Application
-
Alternative Names
Spink2; Serine protease inhibitor Kazal-type 2
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8BMY7
-
Expression Region
17-86aa
-
Molecular Weight
15.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Spink2, or serine peptidase inhibitor Kazal-type 2, is a protein that plays a crucial role in modulating protease activity and maintaining protease homeostasis within tissues, particularly in the pancreas. Research has indicated that Spink2 is involved in several physiological processes and may act as a protective factor against tissue damage, especially in the context of pancreatic diseases. Elevated levels of Spink2 have been associated with conditions such as acute pancreatitis, where it may serve as a compensatory response to excessive proteolytic activity. Given its significant role in pathophysiology, the study of recombinant Spink2 protein has garnered attention for its potential therapeutic implications. By producing recombinant Spink2, researchers aim to elucidate its structure-function relationship, investigate its inhibitory mechanisms on serine proteases, and explore its interaction with other proteolytic enzymes. This research is essential for understanding how Spink2 can be leveraged to develop novel therapeutic strategies for pancreatic disorders and possibly other diseases characterized by dysregulated protease activity. The recombinant form of this protein can also be utilized in biochemical assays and drug development to evaluate its efficacy as a therapeutic agent or biomarker. Through these studies, insights into the molecular mechanisms governed by Spink2 can be achieved, potentially leading to advancements in the management of acute and chronic pancreatic conditions. Overall, recombinant Spink2 protein research stands at the intersection of basic science and clinical application, highlighting its importance in both cellular regulation and potential clinical breakthroughs.
